CVM FOIA Electronic Reading Room
Approved CVM Key Initiatives
Policy Statements
Administrative Staff Manuals
Product Approval Information
- Freedom of Information (FOI) Summaries for Approved and Conditionally Approved Animal Drugs
- Veterinary Master Files
- Environmental Impact Considerations
- NSAID Labels
- Method of Analysis N-methyl-2-pyrrolidone
Enforcement Discretion
Analytical Methods
Persons using assistive technology may not be able to fully access information in these methods. For assistance, please email AskCVM@fda.hhs.gov or call 240-402-7002.
- Quantitative Procedure for Residues of Albendazole in Cattle Liver
- Determination of Amprolium in Eggs and Meat and Meat Products of Chickens
- Determination of Apramycin in Swine Tissue
- Determinative and Confirmatory Procedures for the Assay of Fenbendazole Sulfone in Chicken Egg using LC-MS/MS
- Determination of Carbadox (as Quinoxaline-2-Carboxylic [QCA]) Residues in Swine Liver and Muscle Tissues After Drug Withdrawal
- Determinative and Confirmatory Procedures for Fenbendazole Sulfone in Liver Tissues of Broiler Chicken Using LC-MS/MS, Version 6.0
- Determinative and Confirmatory Procedures for the Detection of Fenbendazole in Liver Tissues of Swine Using LC-MS/MS v. 6.0
- Determinative and Confirmatory Procedures for the Analysis of Fenbendazole Sulfone in Turkey Liver Tissue Using LC-MS/MS, Version 9.0
- Determination and Confirmation of Lubabegron in Bovine Liver Tissue by LC-MS/MS
- Determination and Confirmation Analysis of Lufenuron Residues in Salmon and Trout Tissue by Liquid Chromatography-Tandem Mass Spectrometry Atmospheric Pressure Chemical Ionization (LC-MS/MS APCI)
- Determinative and Confirmatory Procedures for the Analysis of Oxfendazole in Cattle Milk Using LC-MS/MS, Version 6
Compliance & Enforcement
- 483 Syngene International February 2025 Redacted
- Warning Letters
- Advisory Action Letters
- Medicated Feeds
- Ruminant Feed Inspections
- CVM Letter to Feed and Feed Ingredient Manufacturers
- Establishment Inspection Report - Gambol Pet Products Co.
- Establishment Inspection Report - Jinan Uniwell Pet Food Co., Ltd.
- Establishment Inspection Report - Shandong Honva Food Co. Ltd.
- Establishment Inspection Report - Shandong Petswell Food Co. Ltd.
- 2010 Jerky Complaints
- 2011 Jerky Complaints
- 2012-January 2013 Jerky Complaints
- February 2013-September 2013 Jerky Complaints
- September 2013-May 2014 Jerky Complaints
- May-September 2014 Jerky Complaints
- Establishment Inspection Report - Yantai Aska Food
- Yantai Aska Foods 483
- Establishment Inspection Report - Acidchem
- Letter to Kasel Associates Industries, Inc. - Notification of Opportunity to Initiate a Voluntary Recall
- Norbrook Lab Inspectional Observations - 1/20/2020-2/7/2020
- Eric Nelson Calendar February 2025 FOIA 2025-2241
- Flynn Calendar January - February 2024
- Charlotte Conway Calendar January 2, 2023 - January 31, 2023
- Charlotte Conway Calendar January 30, 2023 - March 5, 2023
- Tracey Forfa Calendar January 1, 2019 - March 31, 2019
- Eric Nelson Calendar December 30, 2019 - August 2, 2020 FOIA 2020-6396
- Eric Nelson Calendar Follow up for December 30 to August 2 FOIA 2020-6396
Safety & Health
- AAFCO Annual Meeting 2025 FOIA 2025-9523
- Adverse Event Reports for Animal Drugs and Devices
- Veterinary Medicine Advisory Committee
- Target Animal Safety Review Memorandum: Trace Metal Analysis of Commercial Pet Food for Toxic Metals
- Food and Drug Administration/Center for Veterinary Medicine Report on the Risk from Pentobarbital in Dog Food
CVM's researchers have concluded that the low levels of exposure to pentobarbital that dogs might receive through pet food is unlikely to cause them any adverse health effects. - FDA Records Related to Nestle Purina Beneful Dry Dog Food
- Response for Request for Adverse Event Reports Received for Afoxolaner, Fluralaner, Lotilaner, and Sarolaner
- FDA CVM Comprehensive ADE Report Listing for Afoxolaner (Nexgard): 9/4/13 - 7/31/18
- FDA CVM Comprehensive ADE Report Listing for Fluralaner (Bravecto): 9/4/13 - 7/31/18
- FDA CVM Comprehensive ADE Report Listing for Lotilaner (Credelio): 9/4/13 - 7/31/18
- FDA CVM Comprehensive ADE Report Listing for Sarolaner (Simparica): 9/4/13 - 7/31/18
- Dr. Steven Solomon Presentation -- NGFA‐PFI FEED AND PET FOOD JOINT CONFERENCE -- September 2018
- AFIA Salmonella Webcast PowerPoint – April 2010
Canine Dilated Cardiomyopathy
- FDA CVM FOIA-2019-1704-001147 - FDA CVM FOIA-2019-1704-001161
- FDA CVM FOIA 2019-1704-001191 - FDA CVM FOIA 2019-1704-003926
- FDA CVM FOIA 2019-1704-001255 - FDA CVM FOIA 2019-1704-007577
- FDA-CVM-FOIA-2019-1704-001174 - FDA-CVM-FOIA-2019-1704-006003
- FDA-CVM-FOIA-2019-1704-006219 - FDA-CVM-FOIA-2019-1704-007609
- FDA-CVM-FOIA-2019-1704-001150 - FDA-CVM-FOIA-2019-1704-003878
- FDA-CVM-FOIA-2019-1704-003881 - FDA-CVM-FOIA-2019-1704-007572
- FDA-CVM-FOIA-2019-1704-001220 - FDA-CVM-FOIA-2019-1704-003375
- FDA-CVM-FOIA-2019-1704-003383 - FDA-CVM-FOIA-2019-1704-005966
- FDA-CVM-FOIA-2019-1704-005970 - FDA-CVM-FOIA-2019-1704-007592
- FDA-CVM-FOIA-2019-1704-001611 - FDA-CVM-FOIA-2019-1704-008063
- FDA-CVM-FOIA-2019-1704-008064 - FDA-CVM-FOIA-2019-1704-015075
- FDA-CVM-FOIA-2019-1704-001611 - FDA-CVM-FOIA-2019-1704-009511
- FDA-CVM-FOIA-2019-1704-009522 - FDA-CVM-FOIA-2019-1704-011552
- FDA-CVM-FOIA-2019-1704-011559 - FDA-CVM-FOIA-2019-1704-013713
- FDA-CVM-FOIA-2019-1704-013716 - FDA-CVM-FOIA-2019-1704-014895
- FDA-CVM-FOIA-2019-1704-014896 - FDA-CVM-FOIA-2019-1704-015185
- FDA-CVM-FOIA-2019-1704-001355 - FDA-CVM-FOIA-2019-1704-010458
- FDA-CVM-FOIA-2019-1704-011203 - FDA-CVM-FOIA-2019-1704-012278
- FDA-CVM-FOIA-2019-1704-012279 - FDA-CVM-FOIA-2019-1704-014284
- FDA-CVM-FOIA-2019-1704-014285 - FDA-CVM-FOIA-2019-1704-015385
- FDA-CVM-FOIA-2019-1704-002503 - FDA-CVM-FOIA-2019-1704-002744
- FDA CVM FOIA-2019-1704-000001 - FDA CVM FOIA-2019-1704-000117
- FDA CVM FOIA-2019-1704-000118 - FDA CVM FOIA-2019-1704-000522
- FDA CVM FOIA-2019-1704-000523 - FDA CVM FOIA-2019-1704-000700
- FDA CVM FOIA-2019-1704-000701 - FDA CVM FOIA-2019-1704-001146
- FDA CVM FOIA-2019-1704-001162 - FDA CVM FOIA-2019-1704-005892
- FDA CVM FOIA-2019-1704-005921 - FDA CVM FOIA-2019-1704-010294
- FDA CVM FOIA-2019-1704-010297 - FDA CVM FOIA-2019-1704-011237
- FDA CVM FOIA-2019-1704-011507 - FDA CVM FOIA-2019-1704-013797
- FDA CVM FOIA-2019-1704-013878 - FDA CVM FOIA-2019-1704-015207
- FDA CVM FOIA-2019-1704-015208 - FDA CVM FOIA-2019-1704-015676
- FDA CVM FOIA-2019-1704-015677 - FDA CVM FOIA-2019-1704-016176
- FDA CVM FOIA-2019-1704-016177 - FDA CVM FOIA-2019-1704-016517
- FDA CVM FOIA-2019-1704-016518 - FDA CVM FOIA-2019-1704-016808
- FDA CVM FOIA-2019-1704-016809 - FDA CVM FOIA-2019-1704-017325
- FDA CVM FOIA-2019-1704-017326 - FDA CVM FOIA-2019-1704-017770
- FDA CVM FOIA-2019-1704-017771 - FDA CVM FOIA-2019-1704-018116
- FDA CVM FOIA-2019-1704-018117 - FDA CVM FOIA-2019-1704-018662
- FDA CVM FOIA-2019-1704-018663 - FDA CVM FOIA-2019-1704-019385
High Pressure Processing (HPP) – FOIA 2018-7843
- FDA-CVM-FOIA-Case-1-20-cv-00656-000002780 - FDA-CVM-FOIA-Case-1-20-cv-00656-000002784
- FDA-CVM-FOIA-Case-1-20-cv-00656-000004099
- FDA-CVM-FOIA-Case-1-20-cv-00656-000004100 - FDA-CVM-FOIA-Case-1-20-cv-00656-000004118
Adverse Event Reports
- Adverse Event Reports - May 1, 2010-May 1, 2011
- Adverse Event Reports - May 2, 2011-May 1, 2012
- Adverse Event Reports - May 2, 2012-May 1, 2013
- Adverse Event Reports - May 2, 2013-May 1, 2014 - Part 1
- Adverse Event Reports - May 2, 2013-May 1, 2014 - Part 2
- Adverse Event Reports - May 2, 2013-May 1, 2014 - Part 3
- Adverse Event Reports - May 2, 2014-May 1, 2015
- Adverse Event Reports - May 2, 2015-May 1, 2016
- Adverse Event Reports - May 2, 2016-May 1, 2017
- Adverse Event Reports - May 2, 2017-May 1, 2018
- Adverse Event Reports - May 2, 2018-May 1, 2019
- Adverse Event Reports - May 2, 2019-May 1, 2020
- Adverse Event Reports - May 2, 2020-May 1, 2021
- Adverse Event Reports - May 2, 2021-June 10, 2022
- Adverse Event Reports - June 11, 2022-November 30, 2022
- Adverse Event Reports - December 1, 2022-June 27, 2023
- Adverse Event Reports - June 28, 2023-January 31, 2024
- Adverse Event Reports - February 1, 2024-June 30, 2024
- Adverse Event Reports - July 1, 2024-December 31, 2024
- Adverse Event Reports - January 1, 2025-June 30, 2025
Librela
- Standard Adverse Event Review: Librela
- Response for Request for Adverse Event Reports Received for Bedinvetmab (Librela)
- FDA ADE Report Bedinvetmab (Librela): 5/5/2023- 6/30/2026
- FDA ADE Report Bedinvetmab (Librela): 5/5/2023- 3/31/2026
- FDA ADE Report Bedinvetmab (Librela): 5/5/2023- 12/31/2025
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-9/30/2025
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-6/30/2025
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-3/31/2025
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-3/31/2024
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-6/30/2024
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-9/30/2024
- FDA ADE Report - Bedinvetmab (Librela): 5/5/2023-12/31/2024
Solensia
- Response for Request for Adverse Event Reports Received for Frunevetmab (Solensia)
- FDA ADE Report- Frunevetmab (Solensia): 1/13/2022- 6/30/2026
- FDA ADE Report- Frunevetmab (Solensia): 1/13/2022- 3/31/2026
- FDA ADE Report- Frunevetmab (Solensia): 1/13/2022- 12/31/2025
- FDA ADE Report - Frunevetmab (Solensia): 1/13/2022-9/30/2025
- FDA ADE Report - Frunevetmab (Solensia): 1/13/2022-6/30/2025
- FDA ADE Report - Frunevetmab (Solensia): 1/13/2022-3/31/2025
- FDA ADE Report - Frunevetmab (Solensia): 5/5/2023-3/31/2024
- FDA ADE Report - Frunevetmab (Solensia): 1/13/2022-6/30/2024
- FDA ADE Report - Frunevetmab (Solensia): 1/13/2022-9/30/2024
- FDA ADE Report - Frunevetmab (Solensia): 1/13/2022-12/31/2024